組織診断薬市場：製品、技術、適応症、エンドユーザー別-2024-2030年の世界予測

組織診断薬市場規模は、2023年に83億米ドルと推計され、2024年には89億4,000万米ドルに達し、CAGR 7.76％で2030年には140億2,000万米ドルに達すると予測されています。

組織診断薬は、病気や状態を診断するために患者の体から採取した組織サンプルを検査・分析する医療分野です。がんやその他の組織関連疾患を含む様々な病状の診断・治療に極めて重要です。組織診断薬はいくつかの臨床分野に応用され、病気の早期発見を助ける個別化医療において極めて重要です。世界のがん罹患率の増加と高齢化が、組織診断サービスの需要を牽引しています。ゲノミクスの進歩により、疾患に関連する数多くのバイオマーカーが同定され、正確な診断テストの必要性がさらに高まっています。しかし、診断機器やサービスに関連する高額なコストは、小規模ヘルスケアプロバイダーや低資源環境での採用を妨げる可能性があります。また、複雑な検査結果を解釈できる熟練した専門家が不足していることや、病理医が世界的に不足していることが、市場拡大の妨げになる可能性があります。人工知能（AI）とデジタル病理学との統合などの技術的進歩は、市場プレーヤーに新たな機会をもたらしています。AIベースのアルゴリズムは、見落としやすい組織内の微妙な形態学的変化を検出する際に病理医を支援することができます。さらに、ヘルスケア・インフラに対する政府や民間組織からの投資の拡大が、この分野の成長の道をさらに開くと期待されています。

製品組織サンプルを効率的に処理・分析する組織処理システムの利用が拡大

アクセサリーは、機器や消耗品の機能を補完することで、正確な組織診断を保証する上で極めて重要です。アクセサリーは一般的に、主要な組織診断機器や装置とともに使用される幅広い補助製品やコンポーネントを指します。これらのアクセサリーは、組織診断ツールや機器の性能、効率、機能性を向上させます。消耗品は、組織サンプルの調製、染色、分析、保存の様々なステップに不可欠な特定のバイオマーカーを検出します。組織診断ラボの日々の業務に欠かせないものです。組織診断薬市場には、組織サンプルの収集、処理、分析、診断のための様々な機器や装置が含まれます。これらの機器は、組織標本を正確に評価するために不可欠であり、病理学、組織学、臨床診断学などの分野で重要な役割を果たしています。組織診断ソフトウェア・ソリューションは、スキャンしたスライドから得られたデジタル画像の処理、保存、分析を可能にします。機械学習アルゴリズムと人工知能は、病理医間の遠隔コンサルテーションを促進する診断プログラムに利用されています。これらの先端技術は、より正確で精密な診断を提供し、患者ケアと治療成績の向上を保証します。

テクノロジーデジタル化された組織学的サンプルをコンピューター技術で管理するデジタル病理学技術の採用

デジタル病理学は、デジタル化された組織学的サンプルから生成された情報を管理するためにコンピュータ技術を使用します。デジタル病理システムは、デジタルスライドの効率的な診断、解釈、画像分析、保存、共有を可能にします。精度の向上と所要時間の短縮により、世界中の病理医にとって不可欠なツールとなっています。免疫組織化学（IHC）は、酵素標識抗体をマーカーとして、抗原抗体相互作用により組織サンプル中の特定のタンパク質を検出する方法です。この方法は、腫瘍細胞やその周辺組織に関連する特異的なバイオマーカーを同定することにより、がんなどの様々な疾患の診断に重要な役割を果たしています。in situ hybridization（ISH）は、組織サンプル中の細胞内の特定のRNAまたはDNA配列を検出する技術です。この方法は、遺伝子発現パターン、染色体異常、コピー数の変化を評価するのに役立ちます。蛍光in situハイブリダイゼーションは、検出に蛍光プローブを利用します。特殊な染色技術は、組織学的サンプル内の特定の細胞成分を可視化したり、特定の構造を強調したりします。IHCとISHは組織の分子特性を理解し、特異的なバイオマーカーを検出するために極めて重要です。特殊な染色技術は、従来の方法では見えなかった細胞構造について、さらなる洞察を提供します。

適応症数多くのがん種の検出と特性解析における組織診断薬の急速な普及

組織診断薬は、乳がんの早期発見と特性解析において極めて重要な役割を果たし、患者の予後を改善するための個別化治療を可能にします。免疫組織化学（IHC）や蛍光in situハイブリダイゼーション（FISH）のような技術は、ホルモン受容体の状態を同定するために広く使用されており、標的治療の決定を導いています。組織診断薬を用いた胃がんの異なるサブタイプの同定は、臨床医の予後予測や治療選択を支援します。IHCは、HER2過剰発現のような分子バイオマーカーを検出するために一般的に使用され、トラスツズマブのような標的療法の使用を指示します。リンパ腫は免疫系細胞が関与する不均一な悪性腫瘍群であるため、正確な診断と亜型分類は適切な治療計画にとって極めて重要です。組織診断技術は、ホジキンリンパ腫と非ホジキンリンパ腫を鑑別するための特異的細胞マーカーを同定することができ、さらにはこれらのカテゴリー内のサブタイプを同定することができます。組織診断薬は、EGFR変異、ALK再配列、PD-L1発現レベルなどの遺伝子変化の同定に役立ち、治療決定の指針となります。前立腺がんは、世界的に男性で2番目に多いがんです。組織診断薬は、グリソンスコアリングによる腫瘍の病理学的悪性度の判定や、Ki-67やPTEN欠損などの予後マーカーの評価に極めて重要です。

エンドユーザー：臨床病理検査室における組織診断薬の活用は、患者の治療の質を向上させます。

臨床病理検査室における組織診断薬の主なニーズは、様々な疾患を分子レベルで検出・診断することです。免疫組織化学（IHC）、in situハイブリダイゼーション（ISH）、ヘマトキシリン（H&E）染色などの技術を用いて、病理医が特定の疾患に関連するバイオマーカーを同定するのに役立ちます。医薬品開発業務受託機関（CRO）は、製薬会社やバイオテクノロジー企業の前臨床試験や臨床試験において、調査サービスを必要としています。これらの組織は、組織診断ソリューションを選択する際に、費用対効果、拡張性、納期を優先します。組織診断薬は、病院での患者診断、治療選択、疾患モニタリングに不可欠です。病院は、コストを最小限に抑えながら患者ケアの質を向上させるために、最小の所要時間で正確な結果を提供する信頼性の高い診断ソリューションを必要としています。製薬会社は、薬剤開発や臨床試験に組織診断薬を活用し、精密医療のターゲット集団を特定し、患者の層別化を最適化し、治療反応をリアルタイムで評価するソリューションが必要です。学術・研究機関では、疾病メカニズムの調査、新規バイオマーカーの発見、治療開発の推進のために、最先端の組織診断ソリューションを必要としています。このような研究機関は、ハイスループット解析とマルチプレックス機能をサポートする革新的なテクノロジーを好みます。

地域別インサイト

南北アメリカは、先進的なヘルスケアインフラと主要メーカーによる診断検査開発への広範な研究資金により、市場情勢において重要な位置を占めています。同地域のメーカーは、組織診断薬技術の革新に対してFDAから数多くの特許を取得しています。EMEA地域は、診断技術を向上させるために、がんなどの病気の早期診断の研究開発を支援するために政府が多額の投資を行っているため、組織診断薬市場は新興国市場の様相を呈しています。組織診断薬消耗品の安全性と品質に関する政府の基準や規制も、同地域の市場成長に寄与しています。南アフリカはアフリカ大陸における技術革新の拠点であり、現地の疾患流行パターンに対応した効率的な診断ツールの開発に焦点を当てた研究イニシアチブがいくつか進行中です。新興国市場のAPAC地域は、技術の進歩、最先端の組織診断技術の研究開発への投資、がん罹患率の増加、診断機器の現地生産を奨励する政府の取り組みにより新興国市場として成長しており、同国の産業界におけるイノベーションを促進しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは組織診断薬市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、組織診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.組織診断薬市場の市場規模および予測は？

2.組織診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.組織診断薬市場の技術動向と規制枠組みは？

4.組織診断薬市場における主要ベンダーの市場シェアは？

5.組織診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがんの発生率が増加
    • 個別化医療の利用拡大
    • 効果的かつ早期のがん診断に関する意識を高める政府の取り組み
  • 抑制要因
    • 組織診断にかかる高額な費用と償還の問題
  • 機会
    • デジタル病理学と自動化の始まり組織診断薬
    • 組織診断分野における革新的な技術と機器の開発
  • 課題
    • 組織診断薬手順に関連する制限とプライバシーに関する懸念
• 市場セグメンテーション分析
  • 製品：診断用組織サンプルの効率的な処理と分析のための組織処理システムの普及
  • 技術：コンピュータ技術によるデジタル化された組織学的サンプルの管理のためのデジタル病理学技術の採用
  • 適応症：多数のがん種の検出と特徴付けにおける組織診断薬の指数関数的使用
  • エンドユーザー：臨床病理学研究室で組織診断薬を活用して患者ケアの質を向上させる
• 市場動向分析
  • 南北アメリカにおける組織診断技術の承認取得に重点を置く
  • アジア太平洋地域における慢性疾患の早期発見とスクリーニングを促進する政府の取り組み
  • EMEA地域における組織診断技術の革命的な進歩
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 組織診断薬市場：製品別

• アクセサリー
• 消耗品
• 機器
• ソフトウェア

第7章 組織診断薬市場：技術別

• デジタル病理学とワークフロー
• 免疫組織化学
• インサイチューハイブリダイゼーション
• 特殊染色

第8章 組織診断薬市場適応症別

• 乳がん
• 胃がん
• リンパ腫
• 非小細胞肺がん
• 前立腺がん

第9章 組織診断薬市場：エンドユーザー別

• 臨床病理学
• 契約調査機関
• 病院
• 製薬団体
• 調査室

第10章 南北アメリカの組織診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の組織診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの組織診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • PathAI、エンドツーエンドの中央病理学および組織学サービスを提供するためにバイオファーマラボの拡張を発表
  • Ibex、がん診断におけるAIの世界の導入を推進するためシリーズC資金調達で5,500万米ドルを調達
  • クエスト・ダイアグノスティクス、診断とグレーディングの改善を目指した新しい前立腺がん検査を発表
  • サイテラブス、南インド全域の病院と患者に診断サービスを拡大
  • バイオテクネ、空間生物学によるがん診断を強化するためルナフォアを買収
  • Lunaphoreが4,000万スイスフランを確保し、組織診断薬ソリューションのポートフォリオを強化
  • 免疫組織化学用の新しい試薬ソリューション「Optimer-Fc」の発売
  • アイベックスとアルバーノ・ラボラトリーズ、がん診断のためのAIの複数年、複数組織拡張契約を締結
  • ロシュ、ヤンセンとの連携を拡大し、コンパニオン診断を通じて個別化ヘルスケアを推進
  • ガーダントヘルス、がんバイオマーカー検出を強化するため、ルニットのPd-L1向けAIベーススコアリングアルゴリズムをポートフォリオに統合
  • EprediaとAiforiaがRegenMed Hubイノベーションアクセラレーターに参加、再生医療におけるPHCグループのプレゼンス拡大パートナーシップが新たなRegenMed臨床試験カタリストプログラムへの道を開く
  • マイクロソフト、がんの診断と治療の進歩に向けペイジと提携
  • アジレントとアコヤ・バイオサイエンス、バイオ医薬品アプリケーション向けマルチプレックス組織アッセイ開発を推進する提携を発表
  • TempusがNGSベースの体外診断装置 xT CDxの米国FDA承認を取得
  • ROCHE組織診断薬がマラナ拡張プロジェクトを祝う

第14章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. TISSUE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. TISSUE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. TISSUE DIAGNOSTICS MARKET DYNAMICS
• FIGURE 7. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 16. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 18. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. TISSUE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 24. TISSUE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TISSUE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY ACCESSORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PROBES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SCANNERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SCANNERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SLIDE-STAINING SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SLIDE-STAINING SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TISSUE MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TISSUE MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TISSUE-PROCESSING SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TISSUE-PROCESSING SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY & WORKFLOW, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY DIGITAL PATHOLOGY & WORKFLOW, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL TISSUE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 95. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 96. ARGENTINA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 105. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 106. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 107. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 108. BRAZIL TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 109. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 110. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 111. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 112. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 113. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 114. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 115. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 116. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 117. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 118. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 119. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 120. CANADA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 130. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 131. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 132. MEXICO TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 143. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 144. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 145. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 146. UNITED STATES TISSUE DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 157. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 158. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 159. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 160. ASIA-PACIFIC TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 169. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 170. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 171. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 172. AUSTRALIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 173. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 174. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 175. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 176. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 177. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 178. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 179. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 182. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 183. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 184. CHINA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 185. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 186. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 187. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 188. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 189. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 190. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 191. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 192. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 193. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 194. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 195. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 196. INDIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 203. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 206. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 207. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 208. INDONESIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 215. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 216. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 217. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 218. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 219. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 220. JAPAN TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 227. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 228. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 229. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 230. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 231. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 232. MALAYSIA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 239. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 242. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 243. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 244. PHILIPPINES TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 251. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 252. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 253. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 254. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 255. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 256. SINGAPORE TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 265. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 266. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 267. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 268. SOUTH KOREA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 275. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 276. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 277. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 278. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 279. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 280. TAIWAN TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 287. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 288. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 289. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 290. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 291. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 292. THAILAND TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 299. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 300. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 301. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 302. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 303. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 304. VIETNAM TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 313. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 314. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 315. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 316. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 317. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 318. EUROPE, MIDDLE EAST & AFRICA TISSUE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 325. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 326. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 327. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 328. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 329. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 330. DENMARK TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 335. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 336. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 337. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 338. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 339. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 340. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 341. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 342. EGYPT TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 343. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
• TABLE 344. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
• TABLE 345. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2023 (USD MILLION)
• TABLE 346. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2024-2030 (USD MILLION)
• TABLE 347. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2023 (USD MILLION)
• TABLE 348. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2024-2030 (USD MILLION)
• TABLE 349. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 350. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 351. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2018-2023 (USD MILLION)
• TABLE 352. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY INDICATIONS, 2024-2030 (USD MILLION)
• TABLE 353. FINLAND TISSUE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (US

[196 Pages Report] The Tissue Diagnostics Market size was estimated at USD 8.30 billion in 2023 and expected to reach USD 8.94 billion in 2024, at a CAGR 7.76% to reach USD 14.02 billion by 2030.

Tissue diagnostics is a medical field that involves examining and analyzing tissue samples from a patient's body to diagnose diseases or conditions. It is crucial in diagnosing and treating various medical conditions, including cancer and other tissue-related diseases. Tissue diagnostics has applications across several clinical areas and is crucial in personalized medicine for assisting in early disease detection. An increase in global cancer prevalence rates and an aging population drive the demand for tissue diagnostic services. Advancements in genomics have led to the identification of numerous biomarkers associated with diseases, which have further spurred the need for accurate diagnostic tests. However, high costs associated with diagnostic instruments and services might impede their adoption by small-scale healthcare providers or low-resource settings. The lack of skilled professionals capable of interpreting complex test results and insufficient pathologists worldwide could hinder market expansion. Technological advances such as artificial intelligence (AI) integration with digital pathology have opened up new opportunities for the market players. AI-based algorithms can aid pathologists in detecting subtle morphological changes within tissues that may be easily overlooked. Additionally, growing investments from governments and private organizations towards healthcare infrastructure are expected to provide more avenues for growth in this sector.

Product: Proliferating use of tissue-processing systems for efficient processing and analyzing diagnosing tissue samples

Accessories are crucial in ensuring precise tissue diagnosis by complementing the function of instruments and consumables. Accessories typically refer to a wide range of supplementary products and components used with the primary tissue diagnostic instruments and equipment. These accessories enhance tissue diagnostic tools and devices' performance, efficiency, and functionality. Consumable products detect specific biomarkers essential for various steps in tissue sample preparation, staining, analysis, and storage. They are integral to the day-to-day operations of tissue diagnostic laboratories. The tissue diagnostics market encompasses various instruments and equipment for collecting, processing, analyzing, and diagnosing tissue samples. These instruments are essential for accurately assessing tissue specimens and play a crucial role in fields such as pathology, histology, and clinical diagnostics. Tissue diagnostic software solutions enable the processing, storing, and analyzing digital images obtained from scanned slides. Machine learning algorithms and artificial intelligence are utilized in diagnostics programs to facilitate remote consultations between pathologists. These advanced technologies provide more accurate and precise diagnoses, ensuring enhanced patient care and treatment outcomes.

Technology: Adoption of digital pathology technology for the management of digitized histological samples through computer technology

Digital pathology uses computer technology to manage information generated from digitized histological samples. Digital pathology systems enable efficient diagnosis, interpretation, image analysis, storage, and sharing of digital slides. The increased accuracy and reduced turnaround time make it an essential tool for pathologists worldwide. Immunohistochemistry (IHC) is a method utilized to detect specific proteins in tissue samples through antigen-antibody interactions using enzyme-labeled antibodies as markers. This method plays a vital role in diagnosing various diseases, such as cancer, by identifying specific biomarkers associated with tumor cells or surrounding tissues. In situ hybridization (ISH) is a technique that detects specific RNA or DNA sequences within cells in tissue samples. This method helps evaluate gene expression patterns, chromosomal abnormalities, and copy number variations. Fluorescence in situ hybridization utilizes fluorescent probes for detection. Special staining techniques visualize specific cellular components or highlight certain structures within histological samples. Digital pathology offers significant advantages in terms of efficiency, accuracy, and collaboration potential, while IHC and ISH are crucial for understanding the molecular characteristics of tissues and detecting specific biomarkers. Special staining techniques provide additional insights into cellular structures not visible through conventional methods.

Indications: Exponential use of tissue diagnostics in the detection and characterization of numerous cancer types

Tissue diagnostics play a pivotal role in the early detection and characterization of breast cancer, allowing personalized therapies to improve patient outcomes. Techniques such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are widely used to identify hormone receptor status, guiding targeted therapy decisions. Identifying different subtypes of gastric cancer using tissue diagnostics assists clinicians with prognosis prediction and therapy selection. IHC is commonly employed to detect molecular biomarkers such as HER2 overexpression that directs the use of targeted therapies such as trastuzumab. Accurate diagnosis and subtyping of lymphoma are crucial for appropriate treatment planning since it comprises a heterogeneous group of malignancies involving immune system cells. Tissue diagnostic techniques can identify specific cell markers to differentiate between Hodgkin's and non-Hodgkin's lymphomas or even identify subtypes within these categories. Tissue diagnostics helps identify genetic alterations such as EGFR mutations, ALK rearrangements, and PD-L1 expression levels that can guide treatment decisions. Prostate cancer is the second most common cancer among men globally. Tissue diagnostics are crucial for determining the pathological grade of tumors through Gleason scoring and evaluating prognostic markers such as Ki-67 and PTEN loss.

End-User: Significant utilization of tissue diagnostics in clinical pathology laboratories to improve patient care quality

The primary need for tissue diagnostics in clinical pathology laboratories is to detect and diagnose various diseases at the molecular level. It helps pathologists identify biomarkers associated with specific diseases using techniques such as immunohistochemistry (IHC), in situ hybridization (ISH), and hematoxylin (H&E) staining. Contract research organizations (CROs) require tissue diagnostics services for preclinical and clinical research studies for pharmaceutical companies and biotechnology firms. These organizations prioritize cost-effectiveness, scalability, and turnaround times in choosing tissue diagnostic solutions. Tissue diagnostics are critical for patient diagnosis, treatment selection, and disease monitoring in hospital settings. Hospitals require reliable diagnostic solutions that provide accurate results with a minimal turnaround time to improve patient care quality while minimizing costs. Pharmaceutical companies utilize tissue diagnostics for drug development and clinical trials, necessitating solutions that identify target populations for precision medicine, optimize patient stratification, and evaluate treatment response in real-time. Academic and research institutions require cutting-edge tissue diagnostic solutions to investigate disease mechanisms, discover novel biomarkers, and advance therapeutic development. These laboratories prefer innovative technologies supporting high-throughput analysis and multiplexing capabilities.

Regional Insights

The Americas has a significant landscape in the tissue diagnostics market owing to advanced healthcare infrastructure and extensive research funding by the key manufacturers in the development of diagnostics tests. The manufacturers in the region have observed numerous patents issued by the FDA for innovations in tissue diagnostics technology. The EMEA region has observed a developing landscape in the tissue diagnostics market due to significant investments made by the government to support research initiatives for early diagnosis of diseases such as cancer to improve diagnostic techniques. Government standards and regulations on the safety and quality of tissue diagnostics consumables have also contributed to the market growth in the region. South Africa is a hub for innovation within the African continent, with several ongoing research initiatives focused on developing efficient diagnostic tools that cater to local disease prevalence patterns. APAC region in the market has a developing growth due to technological advancements, investment in research and development of state-of-the-art tissue diagnostic technologies, increasing cancer incidence, and government initiatives encouraging local manufacturing of diagnostic equipment, fostering innovation within the country's tissue diagnostics industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Tissue Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Tissue Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Tissue Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam Plc, Agilent Technologies, Inc., Atlas Antibodies AB, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenex Laboratories Inc., BioIVT, LLC, bioMerieux SA, Cardinal Health, Inc., Castle Biosciences, Inc., Cell Signaling Technology, Inc., Diagnostic BioSystems Inc., F. Hoffmann-La Roche Ltd, Leica Biosystems by Danaher Corporation, McKesson Corporation, Merck KGaA, MILESTONE MEDICAL Srl, PathAI, Inc., Pfizer Inc., PROGEN Biotechnik GmbH, QIAGEN N.V., Quest Diagnostics Incorporated, Sekisui Diagnostics, LLC, Siemens Healthineers AG, SLEE medical GmbH, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Tissue Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Accessories
  • Consumables
    • Antibodies
    • Kits
    • Probes
    • Reagents

• Instruments
  • Scanners
  • Slide-staining Systems
  • Tissue Microarrays
  • Tissue-processing Systems

• Software

• Technology
  • Digital Pathology & Workflow
  • Immunohistochemistry
  • In Situ Hybridization
  • Special Staining

• Indications
  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Non Small Cell Lung Cancer
  • Prostate Cancer

• End-User
  • Clinical Pathology
  • Contract Research Organization
  • Hospitals
  • Pharmaceutical Organizations
  • Research Laboratories

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Tissue Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Tissue Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Tissue Diagnostics Market?

4. What is the market share of the leading vendors in the Tissue Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Tissue Diagnostics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of cancer worldwide
    • 5.1.1.2. Growing use of personalized medicine
    • 5.1.1.3. Government initiatives to increase awareness regarding effective and early cancer diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost involved in tissue diagnosis and reimbursement issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Inception of digital pathology and automated tissue diagnostics
    • 5.1.3.2. Innovative technologies and instruments development in tissue diagnostic field
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with tissue diagnostics procedures coupled with privacy concerns
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Proliferating use of tissue-processing systems for efficient processing and analyzing diagnosing tissue samples
  • 5.2.2. Technology: Adoption of digital pathology technology for the management of digitized histological samples through computer technology
  • 5.2.3. Indications: Exponential use of tissue diagnostics in the detection and characterization of numerous cancer types
  • 5.2.4. End-User: Significant utilization of tissue diagnostics in clinical pathology laboratories to improve patient care quality
• 5.3. Market Trend Analysis
  • 5.3.1. Significant emphasis on securing approvals for tissue diagnostic technologies in the Americas
  • 5.3.2. Government initiatives to encourage early detection and screening of chronic diseases in the APAC region
  • 5.3.3. Revolutionary advancements in tissue diagnostic technologies in the EMEA region
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Tissue Diagnostics Market, by Product

• 6.1. Introduction
• 6.2. Accessories
• 6.3. Consumables
• 6.4. Instruments
• 6.5. Software

7. Tissue Diagnostics Market, by Technology

• 7.1. Introduction
• 7.2. Digital Pathology & Workflow
• 7.3. Immunohistochemistry
• 7.4. In Situ Hybridization
• 7.5. Special Staining

8. Tissue Diagnostics Market, by Indications

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Gastric Cancer
• 8.4. Lymphoma
• 8.5. Non Small Cell Lung Cancer
• 8.6. Prostate Cancer

9. Tissue Diagnostics Market, by End-User

• 9.1. Introduction
• 9.2. Clinical Pathology
• 9.3. Contract Research Organization
• 9.4. Hospitals
• 9.5. Pharmaceutical Organizations
• 9.6. Research Laboratories

10. Americas Tissue Diagnostics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Tissue Diagnostics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Tissue Diagnostics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services
  • 13.3.2. Ibex Raises USD 55 Million in Series C Funding to Drive Global Adoption of AI for Cancer Diagnosis
  • 13.3.3. Quest Diagnostics Launches Novel Prostate Cancer Test Aimed at Improving Diagnosis and Grading
  • 13.3.4. Cytelabs expanding diagnostic services to hospitals and patients across south India
  • 13.3.5. Bio-Techne Buys Lunaphore to Boost Cancer Diagnostics Through Spatial Biology
  • 13.3.6. Lunaphore Secures Chf 40 Million to Boost Portfolio of Tissue Diagnostics Solutions
  • 13.3.7. Launch of Optimer-Fc as a New Reagent Solution for Immunohistochemistry
  • 13.3.8. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
  • 13.3.9. Roche Expands Collaboration with Janssen to Advance Personalized Healthcare Through Companion Diagnostics
  • 13.3.10. Guardant Health to Integrate Lunit's Ai-Based Scoring Algorithm for Pd-L1 into its Portfolio to Enhance Cancer Biomarker Detection
  • 13.3.11. Epredia and Aiforia Join RegenMed Hub Innovation Accelerator, Expanding PHC Group Presence in Regenerative Medicine Partnership Will Pave the Way for New RegenMed Clinical Trials Catalyst Program
  • 13.3.12. Microsoft Strikes Partnership with Paige to Advance Cancer Diagnostics and Treatment
  • 13.3.13. Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
  • 13.3.14. Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
  • 13.3.15. ROCHE tissue diagnostics celebrates marana expansion project

14. Competitive Portfolio

• 14.1. Key Company Profiles
• 14.2. Key Product Portfolio